Archived Content Notice
You are currently accessing the Think Kidneys website. Please be aware that this site is an archive and contains content from the Think Kidneys project, which concluded in 2019. As a result, the information presented here is no longer being updated or maintained.
For the most current and relevant information, we encourage medical professionals to visit the UK Kidney Association for comprehensive resources and updates in the field. Patients and their families can find valuable, patient-centric information and support at Kidney Care UK.
We would also like to inform you that the Kidney Quality Improvement Partnership (KQIP) is now part of the UK Kidney Association. For more information, please visit KQIP’s homepage under the UK Kidney Association.
We thank you for your understanding and invite you to explore these recommended resources for up-to-date insights and guidance in kidney care and health.
Many medications are cleared via the kidneys, so have the potential to accumulate during an episode of AKI. The result of this may be a further deterioration in kidney function, or there may be other adverse effects. Hence it is necessary to review the use of these medications and amend the doses appropriate to the level of the patient’s renal function.
These guidelines are not exhaustive and are only intended to act as an aide memoire to the medicines optimisation of patients with AKI. For further advice, please contact a renal pharmacist or nephrologist.
Medicines optimisation for AKI